Tildrakizumab for Moderate-to-Severe Plaque Psoriasis Tildrakizumab for Moderate-to-Severe Plaque Psoriasis

Review the latest clinical studies on tildrakizumab, a promising new monoclonal antibody targeting IL-23p19, for patients with moderate-to-severe chronic plaque psoriasis.Skin Therapy Letter
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Related Links:

Conditions:   Psoriasis;   Psoriatic Arthritis Intervention:   Diagnostic Test: Questionary Sponsor:   Bezmialem Vakif University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Plaque Psoriasis Intervention:   Drug: ARQ-151- cream 0.3% Sponsor:   Arcutis Biotherapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion: Lichen Planus Severity Index is a new reproducible tool to grade the severity of lichen planus.
Source: Indian Journal of Dermatology, Venereology and Leprology - Category: Dermatology Authors: Source Type: research
Priyanka Gowda, Veeranna Shastry, P. S. S. Ranugha, Vinutha RangappaIndian Journal of Dermatology, Venereology, and Leprology 2020 86(2):231-231
Source: Indian Journal of Dermatology, Venereology and Leprology - Category: Dermatology Authors: Source Type: research
Conditions:   Mesenchymal Stromal Cells;   Psoriasis;   Drug Effect;   Drug Toxicity Interventions:   Drug: Calcipotriol ointment;   Drug: PSORI-CM01 Granule;   Biological: adipose-derived multipotent mesenchymal stem cells Sponsor:   Guangdong Provincial Hospital of Traditional Chinese Medicine Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Rheumatoid Arthritis;   Psoriasis Interventions:   Other: Harkány medicinal water;   Other: Tap water (placebo control) Sponsors:   University of Pecs;   National Research, Development and Innovation Office, Hungary;   Harkány Spa Hospital, Hungary Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Mesenchymal Stromal Cells;   Psoriasis;   Drug Effect;   Drug Toxicity Interventions:   Drug: Calcipotriol ointment;   Drug: PSORI-CM01 Granule;   Biological: adipose-derived multipotent mesenchymal stem cells Sponsor:   Guangdong Provincial Hospital of Traditional Chinese Medicine Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Rheumatoid Arthritis;   Psoriasis Interventions:   Other: Harkány medicinal water;   Other: Tap water (placebo control) Sponsors:   University of Pecs;   National Research, Development and Innovation Office, Hungary;   Harkány Spa Hospital, Hungary Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: These data suggest biomarker analysis can reflect disease activity across disease domains in PsA. Certain domains would likely benefit from evaluation of additional biomarkers. PMID: 32067517 [PubMed - as supplied by publisher]
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research
WEDNESDAY, Feb. 19, 2020 -- Four drugs have similar Psoriasis Area and Severity Index (PASI) response rates for both short- and long-term treatment of plaque psoriasis, according to a review published online Feb. 5 in JAMA Dermatology. April W....
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Dermatology | Health | Psoriasis | Skin | Study